Mycophenolate mofetil in the treatment of retroperitoneal fibrosis
- 8 January 2008
- journal article
- case report
- Published by Springer Nature in Clinical Rheumatology
- Vol. 27 (5) , 679-681
Abstract
The pathogenesis of idiopathic retroperitoneal fibrosis (IRPF) has been attributed to an autoimmune response to atherosclerotic lipid material leaking from blood vessels. Corticosteroids and cytotoxic agents have been used for therapy. Based on the immunosuppressive and anti-fibrotic action of mycophenolate, we administered this agent to a patient with biopsy-proven IRPF and achieved a rapid, complete and sustained remission with a 6-year follow-up.Keywords
This publication has 11 references indexed in Scilit:
- Combined Prednisone and Mycophenolate Mofetil Treatment for Retroperitoneal FibrosisJournal of Urology, 2007
- Mycophenolate mofetil combined with steroids: New experiences in the treatment of idiopathic retroperitoneal fibrosisVojnosanitetski Pregled, 2007
- Mycophenolate Mofetil Ameliorates Arteriolopathy and Decreases Transforming Growth Factor-β1 in Chronic Cyclosporine NephrotoxicityAmerican Journal of Transplantation, 2003
- Idiopathic retroperitoneal fibrosis and ankylosing spondylitis. A new case reportJoint Bone Spine, 2002
- Treatment of retroperitoneal fibrosis by mycophenolate mofetil and corticosteroidsThe Lancet, 1998
- Long-term follow-up of low-dose methotrexate therapy in one case of idiopathic retroperitoneal fibrosisClinical Rheumatology, 1995
- Periarticular fibrosis associated with idiopathic retroperitoneal fibrosis.1988
- Idiopathic Retroperitoneal Fibrosis. A Retrospective Analysis of 60 CasesBritish Journal of Urology, 1987
- The localisation of immunoglobulin in chronic periaortitisAtherosclerosis, 1986
- THE ASSOCIATION OF RETROPERITONEAL FIBROSIS WITH SYSTEMIC VASCULITIS AND HLA-B27 - A CASE-REPORT AND REVIEW OF THE LITERATURE1981